Pharmaceutical Contract Packaging Market Size, Trends, Analysis and Forecast Report 2026-2034

According to a research report by IMARC Group, the global pharmaceutical contract packaging market size reached USD 24.66 Billion in 2025. The market is projected to reach USD 42.18 Billion by 2034, exhibiting a growth rate (CAGR) of 5.96% during 2026–2034. The United States currently dominates the market, holding a significant market share of over 38.6% in 2025. The market is primarily driven by rising pharmaceutical outsourcing, growing biologics and biosimilar pipelines, stringent global serialization mandates, and increasing demand for specialized sterile and primary packaging solutions.

Key Highlights of the Pharmaceutical Contract Packaging Market Report:

• The global Pharmaceutical Contract Packaging Market reached USD 24.66 Billion in 2025 and is projected to reach USD 42.18 Billion by 2034, registering a CAGR of 5.96% during the forecast period (2026–2034), according to IMARC Group.
• The United States dominates the global pharmaceutical contract packaging market in 2025, holding over 38.6% of the market share, driven by a robust biopharmaceutical sector, full DSCSA serialization enforcement, and high outsourcing rates among large pharma and biotech firms.
• By type, the sterile segment holds the largest share at 57.9% of the market in 2025, owing to the exponential growth of biologics, vaccines, and injectable therapies requiring aseptic processing and contamination-proof primary containment.
• By packaging, plastic bottles represent the dominant packaging format at 28.4% (2025), followed by blister packs (21.7%) and caps and closures (16.3%).
• Key market drivers include rising pharmaceutical outsourcing trends, growing biologics pipeline, and stringent global serialization mandates across North America, Europe, and Asia.
• Key market trends include advancement of patient-centric packaging, sustainable mono-material designs, AI-powered machine vision quality systems, and pre-filled syringe formats growing at an 11.43% CAGR.
• Major market challenges include high capital investment for sterile fill-finish infrastructure, complex cold-chain packaging requirements, and regulatory complexity across multiple jurisdictions.
• Leading players profiled in the report include West Pharmaceutical Services, Inc., PCI Pharma Services, Gerresheimer AG, Sharp Services, LLC, CCL Industries, and NIPRO.

Market Snapshot

Rising Pharmaceutical Outsourcing Trend:

More than 65% of all pharmaceutical brands are contract packaged for blister sealing‚ bottling and labeling․ This offers speed to market‚ rapid regulatory approval and lower in-house infrastructure costs․ Structural changes like these continue in both large pharmaceutical companies and start-up biotechs․ Contract packager outsourcing (CPO) is also popular․ Pharmaceutical contract packaging allows manufacturers to avoid large investments into packaging lines and serialization infrastructure‚ and to be fully compliant with the requirements of its various markets․

Biologics and Biosimilar Pipeline Growth:

Global sterile medicinal product output is projected to grow by 15% CAGR to 2027․ The rapid growth of biologics and vaccines‚ particularly in parenteral dosage forms‚ means aseptic processing environments and contamination-proof primary packaging are vital․ As demand for sterile primary packaging such as syringes‚ vials and ampoules continues to grow with 55 new drugs approved by FDA's CDER‚ the need for complex and multi-functional packaging solutions will also remain․ The pre-filled syringes and auto-injector packaging format will grow at a CAGR of 11․43% due to self-administered biologics․

Stringent Global Serialization Mandates:

The upcoming DSCSA full serialization and aggregation requirements from November 2024 (along with similar requirements in Europe (FMD)‚ Gulf states‚ and Canada) will require all pharmaceutical manufacturers to partner with CPOs that provide proven track and trace solutions‚ driving further growth for outsourcing in packaging and related serialization services․ The error rates seen during the early implementation of DSCSA caused a scramble for serialization systems with open architectures and real-time EPCIS data exchange․ CPOs with harmonized global serialization systems are taking an increasing share of outsourcing contracts away from MNCs․

Ageing Population and Rising Drug Demand:

Pharmaceutical Contract Packaging Market Segmentation Analysis:

By Type

• Sterile
• Non-Sterile

The sterile segment accounts for the largest share, representing 57.9% of the global pharmaceutical contract packaging market in 2025. Its dominance is directly linked to the exponential growth of biologics, biosimilars, vaccines, and parenteral formulations - all of which require aseptic processing environments and contamination-proof primary packaging under stringent GMP Annex 1 and FDA cGMP standards. Non-sterile packaging holds a 42.1% share and serves the large oral solid dosage market, including tablets, capsules, sachets, and powders.

By Packaging

• Plastic Bottles
• Blister Packs
• Caps and Closures
• Bags and Pouches
• Prefilled Syringes
• Vials and Ampoules
• Others

Plastic bottles represent the largest packaging format at 28.4% in 2025 (approximately USD 7.00 Billion). Blister packs hold a 21.7% share, predominantly used for oral solid dose packaging, delivering excellent moisture and oxygen barrier protection alongside patient-friendly unit-dose dispensing. Caps and closures account for 16.3% of the market, driven by innovations in child-resistant, tamper-evident, and senior-friendly closure designs.

By Region

• United States
• Europe
• China
• India
• Rest of World

The United States leads the global pharmaceutical contract packaging market with a 38.6% revenue share in 2025, driven by a highly advanced biopharmaceutical sector, the world's highest pharmaceutical outsourcing rates, and full DSCSA serialization enforcement from November 2024. Europe, at 27.5%, represents the second-largest market, supported by EU Falsified Medicines Directive (FMD) serialization mandates and a large pharmaceutical manufacturing base across Germany, Switzerland, France, and the United Kingdom.

Competitive Landscape in the Pharmaceutical Contract Packaging Industry:

The global pharmaceutical contract packaging market is moderately fragmented‚ with the leading five CPOs and CDMOs expected to account for 35-42% of the global contract packaging revenue by 2025․ Growing demand for specialized‚ sterile and compliant‚ packaging has led to increased investment in R&D and expansion of facilities‚ with regional players emerging to meet needs of specific markets and strengthening competition․ Markets also shifted with Novo Holdings' USD 16․5 Billion acquisition of Catalent and Novo Nordisk committing USD 11 Billion․ There is strong interest from private equity firms especially in mid-tier CPOs with certified sterile capabilities and serialization systems․

Key Pharmaceutical Contract Packaging Market Players Include:

• West Pharmaceutical Services, Inc.
• PCI Pharma Services
• Gerresheimer AG
• Sharp Services, LLC
• CCL Industries
• NIPRO

Market Drivers, Challenges & Opportunities:

Major Market Drivers:

• Rising pharmaceutical outsourcing: Approximately 65% of pharmaceutical brands now rely on contract packagers, delivering operational flexibility, faster regulatory compliance, and reduced in-house infrastructure costs.
• Biologics and sterile packaging boom: Sterile medicinal product output growing at 15% CAGR to 2027, with pre-filled syringes and auto-injector formats advancing at an 11.43% CAGR through 2034.
• Stringent serialization mandates: Full DSCSA enforcement (November 2024), EU FMD, and GCC mandates compelling pharmaceutical manufacturers to engage CPOs with validated track-and-trace platforms globally.

Key Challenges:

• High capital investment requirements: Average cost of establishing a sterile fill-finish line ranges from USD 30–100 million, creating significant barriers for small-to-medium CPOs seeking capacity expansion.
• Complex cold-chain packaging: Rapid growth of temperature-sensitive biologics and mRNA vaccines demands specialized cold-chain infrastructure with continuous temperature monitoring, adding operational complexity and cost.

Emerging Opportunities:

• Sustainable and recyclable packaging: The EU PPWR 2025/40 requiring full recyclability by 2030 is accelerating investment in mono-material packaging designs and post-consumer recycled (PCR) materials.
• Asia Pacific expansion: India and China advancing at 9.1% and 8.7% CAGR through 2035 respectively, with expanding FDA-approved facility bases and cost advantages creating substantial CPO opportunities.
• AI-driven packaging automation: AI-enabled changeover systems, machine vision inspection, and robotic packaging lines are trimming validation cycles and boosting line productivity for CPOs globally.

Conclusion: Pharmaceutical Contract Packaging Market Outlook to 2034:

About the Author

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Construction, Healthcare, Energy, Chemicals, Food & Beverages, Packaging, and more.

Media & Sales Contact

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Business/82667-Pharmaceutical-Contract-Packaging-Market-Size-Trends-Analysis-and-Forecast-Report-2026-2034.html